Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Multiple Sclerosis Drug Prices Rising By Double-Digits Despite Rebates

Executive Summary

Report by the Massachusetts Attorney General’s office offers a unique view of net price trends because it is based on point-of-sale spending and hard-to-get rebate data.

You may also be interested in...



Woodcock Becomes PCORI Board's First FDA Representative

Center for Drug Evaluation and Research director accepts six-year term on Board of Governors of the Patient-Centered Outcomes Research Institute, which funds comparative effectiveness studies.

MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts – ICER Report

List pricing for Biogen’s Tecfidera and Novartis’ Gilenya would need to be discounted 47% and 50%, respectively, for them to be considered good values, ICER concludes in a new report. But three products come in under ICER's thresholds.

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel